 Altretamine Altretamine National Cancer Institute-designated group antineoplastic agent treatment advanced ovarian cancer Altretamine lipid-soluble drug available oral administration capsule drug metabolic oxidation methylol derivatives formaldehyde unclear metabolite major species responsible cytotoxicity primary mechanism cytotoxicity single agent treatment ovarian cancer response rate similar active agents disease percent major utility altretamine combination agents cyclophosphamide doxorubicin fluorouracil melphalan cisplatin trials contribution altretamine multiagent combinations Dose-limiting toxicities gastrointestinal nausea anorexia neurotoxic peripheral neurotoxicity therapeutic role altretamine limited toxicity profile similar cisplatin active agents ovarian cancer use patients candidates standard platinum-based regimens